A new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients in a world-first clinical trial. The treatment targets the Epstein-Barr virus (EBV).
Full story here:
https://reliawire.com/ms-immunotherapy-ebv/
Full story here:
https://reliawire.com/ms-immunotherapy-ebv/
Comment